Trial Profile
PHASE I, OPEN LABEL, MULTICENTER DOSE ESCALATION STUDY OF GLIADEL IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 May 2018
Price :
$35
*
At a glance
- Drugs Carmustine polifeprosan 20 wafer (Primary)
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use
- 21 May 2018 New trial record